Comparing two treatments for prostate cancer recurrence after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II randomized, open-label study evaluates the effectiveness of salvage radiotherapy combined with either androgen-deprivation therapy (ADT) using LHRH agonists or antagonists, or anti-androgen therapy (AAT) with apalutamide in hormone-naïve patients who have experienced biochemical progression after radical prostatectomy. Participants will receive standard salvage radiotherapy and will be randomly assigned to one of the two treatment arms for a duration of six months. The primary objective is to assess sexual function differences between the two groups using the EPIC-26 sexual domain scores at nine months post-treatment initiation. The study aims to explore alternatives to traditional ADT, which can have significant side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male, \> 18 years old.
2. ECOG 0-1.
3. Histologically confirmed adenocarcinoma of the prostate.
4. Previous radical prostatectomy (RP), pT2-3, pN0 or pNx.
5. PSA detectable with confirmed rise (at least 2 weeks apart) at least 8 weeks after RP.
6. Hormone-naive disease.
7. Patients amendable to take oral medication.
8. Patients must have clinical laboratory values at screening:

   1. Hemoglobin 9.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomization
   2. Platelet count ≥100,000 x 109/µL independent of transfusion and/or growth factors within 3 months prior to randomization
   3. Serum albumin ≥3.0 g/dL
   4. Serum creatinine \<2.0 × upper limit of normal (ULN)
   5. Serum potassium ≥3.5 mmol/L
   6. Serum total bilirubin 1.5 × ULN (note: in subjects with Gilbert's syndrome, if total bilirubin is \>1.5 × ULN, measure direct and indirect bilirubin and if direct bilirubin is ≤1.5 × ULN, subject may be eligible)
   7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \<2.5 × ULN
9. Medications known to lower the seizure threshold must be discontinued or substituted at least 4 weeks prior to study entry.
10. Patient agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug.
11. Patients who have received the information sheet and signed the informed consent form.
12. Patients must be willing to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

1. Patients with severe erectile dysfunction according to international index of erectile function (IIEF-5) questionnaire (score 1-7).
2. Allergies, hypersensitivity or known intolerance to the study drugs or excipients.
3. History of any of the following:

   1. Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within 1 year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect).
   2. Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization.
4. Current evidence of any of the following:

   1. Uncontrolled hypertension.
   2. Gastrointestinal disorder affecting absorption.
5. Patients already included in another clinical trial involving an experimental drug.

Where it's running

• OLVZ Aalst
  Aalst, Belgium Recruiting
• AZ Sint-Jan
  Brugge, Belgium Recruiting
• Hopital Erasme
  Bruxelles, Belgium Recruiting
• UZ Gent
  Gent, Belgium Recruiting
• AZ Groeninge
  Kortrijk, Belgium Recruiting
• Gza
  Wilrijk, Belgium Recruiting

Study contacts

• Principal investigator: Piet Dirix — Gasthuis Zusters Antwerpen
• Study coordinator: Ilse Van der Auwera
• Email: ilse.vanderauwera@gza.be
• Phone: 003234433759

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Psilocybin-assisted psychotherapy for anxiety after a cancer diagnosis

  This study will test whether psilocybin-assisted psychotherapy using NPX-5 (25 mg or 10 mg versus a low 1 mg dose) helps adults who have anxiety from adjusting to a cancer diagnosis.

  Recruiting at 5 sites Phase 2 Psyence Australia Pty Ltd · Abbotsford, Victoria and 4 other locations · NCT07072728

• Exercise versus calorie restriction: effects on tumor and muscle protein synthesis in prostate cancer

  This study will test whether daily exercise or cutting calories better changes tumor and muscle protein synthesis in men with early-stage prostate cancer who are scheduled for prostatectomy.

  Recruiting Maastricht University Medical Center · Hasselt · NCT06406803

• Comparing 3D AI-assisted prostate surgery to standard techniques

  This study is testing whether a new 3D robot-assisted prostate surgery can help men with prostate cancer recover better and have fewer complications compared to standard surgery.

  Recruiting at 2 sites Fondazione del Piemonte per l'Oncologia · Candiolo, Turin and 1 other locations · NCT06318559

• Comparing two versus five MRI-guided treatments for prostate cancer

  This study is testing if giving radiation treatment for prostate cancer in just two sessions instead of five can work just as well for men with localized prostate cancer.

  Recruiting Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT05600400

• Combining a new immunotherapy with radiation for prostate cancer treatment

  This study is testing if a new immune treatment combined with radiation can help men with localized high- and intermediate-risk prostate cancer fight their disease better.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05361798

• Reducing sedentary behavior in prostate cancer survivors

  This study is testing if a special program with support and a FitBit can help prostate cancer survivors move more and sit less over 12 weeks.

  Recruiting University of Toronto · Toronto, Ontario · NCT05214937

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.